0/1 Hour Pathway for Myocardial Infarction Shows Safety but No Improvement in ED Throughput

The U.S. Food and Drug Administration (FDA) has approved Mimrylo (rusfertide), marking a significant advancement in the treatment of polycythemia vera, a rare blood disorder characterized by excessive red blood cell production. This first-in-class therapy targets the underlying biology of the condition by mimicking hepcidin, a hormone that regulates iron levels in the body. By limiting iron availability, Mimrylo effectively reduces red blood cell overproduction, offering a new treatment option for patients who have not responded adequately to existing therapies. Polycythemia vera can lead to serious cardiovascular complications, including blood clots, stroke, and heart attack, due to thickened blood. Traditionally, management of the disorder has involved frequent phlebotomies to maintain hematocrit levels below 45%, a process that can be burdensome for patients. The approval of Mimrylo is expected to alleviate some of this burden, as it provides a novel approach to managing the disease without the need for constant blood draws. The efficacy of Mimrylo was demonstrated in the VERIFY trial, a phase 3 study involving 293 adults who required frequent phlebotomies despite standard care. Results showed that 76.9% of patients treated with Mimrylo did not require phlebotomy during the latter part of the study, compared to only 32.9% in the placebo group. Common side effects included injection site reactions and anemia. This approval, granted to Takeda Pharmaceuticals America, Inc., represents a crucial step forward in the management of polycythemia vera, potentially improving the quality of life for many patients.

The American Society for Nutrition (ASN) showcased its latest research and publications at the NUTRITION 2026 conference held in National Harbor. This annual event brings together leading experts in the field of nutrition to discuss recent advancements, share findings, and foster collaboration among professionals. The conference serves as a platform for presenting cutting-edge research that can influence dietary guidelines and public health policies. Key topics discussed included the impact of nutrition on chronic diseases, the role of dietary patterns in health outcomes, and innovative approaches to nutritional interventions. The ASN emphasized the importance of evidence-based nutrition science in addressing global health challenges, particularly in the context of rising obesity rates and related health issues. Healthcare professionals, researchers, and policymakers are encouraged to engage with the findings presented at the conference, as they have significant implications for clinical practice and public health initiatives. The ASN plans to publish the proceedings and key research highlights in its journals, ensuring that the information reaches a wider audience. Looking ahead, ASN aims to continue its commitment to advancing nutrition science and improving health outcomes through ongoing research and education. The organization will also focus on increasing collaboration with other health organizations to address the multifaceted challenges of nutrition in healthcare.